Drug intelligence / Profile preview

ZB022

Development stage: Preclinical
Lead developer: Zenas BioPharma
Modality: Small Molecules
Administration: Oral

Overview

ZB022 is a potentially best-in-class, oral, brain-penetrant allosteric inhibitor of Tyrosine kinase 2 (TYK2), specifically acting via the JH2 domain, with expected improved selectivity and specificity; it is being investigated as a treatment for neuroinflammatory and neurodegenerative diseases. Preclinical studies show favorable pharmacokinetic and pharmacodynamic properties. Initial clinical trials are planned, with an IND submission and Phase 1 study expected to start in 2026.

Targets

TYK2 JH2 (Tyrosine kinase 2 Janus homology 2 pseudokinase domain)

Beyond the preview

Go deeper on ZB022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZB022.

Explore the full profile